Will NVO (Novo Nordisk) Provide Any Buying Opportunity?

Novo Nordisk A/S (NVO), a healthcare company engages in the research, development, manufacture & marketing of the pharmaceutical products worldwide.

Novo Nordisk A/S (NVO), a healthcare company engages in the research, development, manufacture & marketing of the pharmaceutical products worldwide. It operates in two segments, Diabetes & Obesity care & Rare Disease. It is based in Denmark, comes under Healthcare - Biotechnology sector & trades as “NVO” ticker at NYSE.

NVO is trading at all time high in bullish weekly impulse sequence in ((3)) of III & expect to remain supported in 3, 7 or 11 swings pullback to resume higher. It favors upside in (3) & soon will starts correction, that offers trading opportunity.

NVO - Elliott Wave Latest Weekly View: 

In weekly, it placed ((II)) at $15.45 low in November-2016 & (II) at $20.61 low in October-2018. Within (III) sequence, it placed I at $61.08 high & II at $47.51 low in September-2022 low. In I sequence, it placed ((1)) at $32.41 high, ((2)) at $24.62 low, ((3)) at $57.98 high, ((4)) at $45.76 low & ((5)) at $61.08 high. It broke above I high, ended ((1)) of III at $86.48 high & ended correction of ((2)) at $75.56 low in July-2023 low.

NVO - Elliott Wave Latest Daily View: 

Above ((2)) low, it placed (2) at $86.96 low & favors upside in (3) of ((3)) of III. Within (3), it placed 1 at $104 high, 2 as flat correction at $94.73 low, 3 at $138.28 high & 4 at $121.29 low. Above there, it favors upside in 5 & expect two more highs to finish (3) of ((3)), while dips remain above $136.01 low. It has minimum number of swings to call the (3) completed, which confirms below price trendline. We like to buy the pullbacks in (4) or ((4)) at extreme areas while above weekly price trendline.

Source: https://elliottwave-forecast.com/stock-market/will-nvo-provide-buying-opportunity/

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.

STOCKS IN THIS BLOG POST

Comments